Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer

Journal article

Peer reviewed

R. Phillips, J. Proudfoot, E. Davicioni, D.E. Spratt, F.Y. Feng, J. Simko, R.B. Den, A. Pollack, S.A. Rosenthal, O. Sartor, …

International journal of radiation oncology, biology, physics, Vol.117(2), pp.S34-S35

2023-10

Metrics

1 Record Views

Title: Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer
Creators: R. Phillips
J. Proudfoot
E. Davicioni
D.E. Spratt
F.Y. Feng
J. Simko
R.B. Den
A. Pollack
S.A. Rosenthal
O. Sartor
C. Sweeney
G. Attard
S.I. Patel
W.A. Hall
J.A. Efstathiou
A.B. Shah
K.E. Hoffman
S. Pugh
H.M. Sandler
P.T. Tran
Publication Details: International journal of radiation oncology, biology, physics, Vol.117(2), pp.S34-S35
Academic Unit: UMMG Dept of Radiation Oncology; Miller School of Medicine; Leadership Department
Language: English
Resource Type: Journal article
Record Identifier: 991031937556802976